Clinical Trials Search
Clinical Trial 18739
Study Type: Treatment
Phase of Study: Phase I
- Mihaela Druta
A Phase 1 Dose Escalation And Cohort Expansion Study Of ERY974, AN ANTI-GLYPICAN 3 (GPC3)/CD3 Bispecific Antibody, In Patients With Advanced Solid Tumors
The purpose of this study is to find the highest dose of ERY974 which can be safely given to participants with tumors and to find out what effects ERY974 has, good and bad.
DOSE ESCALATION PHASE: To determine the maximum tolerated dose (MTD) of ERY974 in patients with locally advanced or metastatic solid tumors expressing glypican 3 (GPC3). COHORT EXPANSION PHASE: To make a preliminary assessment of the anti-tumor activity of ERY974 in gastric/gastro-esophageal junction (GEJ), esophagus and other GPC3 positive tumors.